Private company
Clearside Biomedical, Inc.
American pharmaceutical preparations company based in Alpharetta.
Last updated Oct 18, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
Where the money goes
Where each dollar of revenue went, fiscal 2024
- Cost of revenue1¢$149.0K
- Research and development99¢$18.6M
Out of $1.7M in revenue.3 The company lost money this year.
Financial statements
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | $30.0K4 | $2.2M5 | $7.9M6 | $29.6M7 | $1.3M3 | $8.2M3 | $1.7M3 |
| Cost of revenue | $07 | $204.0K3 | $355.0K3 | $149.0K3 | |||
| Research and development | $68.3M4 | $15.7M5 | $15.1M6 | $18.5M7 | $19.6M3 | $20.8M3 | $18.6M3 |
| Operating income | -$82.9M4 | -$30.3M5 | -$17.9M6 | -$627.0K7 | -$30.3M3 | -$24.8M3 | -$28.9M3 |
| Net income | -$82.8M4 | -$30.8M5 | -$18.2M6 | $376.0K7 | -$32.9M3 | -$32.5M3 | -$34.4M3 |
| Earnings per share | -$0.815 | -$0.396 | $0.017 | -$0.553 | -$0.533 | -$0.473 | |
| Earnings per share (diluted) | -$0.815 | -$0.396 | $0.017 | -$0.553 | -$0.533 | -$0.473 |
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Cash | $8.0M4 | $22.6M5 | $17.3M6 | $30.4M7 | $48.3M3 | $28.9M3 | $20.0M3 |
| Current assets | $42.9M10 | $25.2M4 | $18.1M5 | $42.1M6 | $49.4M7 | $30.1M3 | $21.3M3 |
| Total assets | $44.1M10 | $26.8M4 | $19.3M5 | $42.9M6 | $51.3M7 | $34.0M3 | $25.1M3 |
| Current liabilities | $10.5M10 | $10.9M4 | $9.9M5 | $4.6M6 | $5.8M7 | $6.8M3 | $4.8M3 |
| Long-term debt | $9.4M10 | $3.8M4 | |||||
| Total liabilities | $20.5M10 | $15.6M4 | $10.6M5 | $4.9M6 | $40.7M7 | $49.9M3 | $64.0M3 |
| Shareholders’ equity | $23.6M5 | $11.2M6 | $8.8M7 | $38.0M3 | $10.6M3 | -$15.9M3 | -$38.9M3 |
| Shares outstanding | 32.1M shares10 | 44.4M shares4 | 51.9M shares5 | 59.7M shares6 | 60.6M shares7 | 62.9M shares3 | 76.6M shares3 |
Leadership
Who has led Clearside Biomedical, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
20202025
- Chief executive officerGeorge M. Lasezkay Apr 10, 2019 to Jan 10, 202511
- Chief executive officerDaniel H. White Jun 1, 2016 to Feb 7, 201912
- PresidentDaniel H. White Jun 1, 2016 to Feb 7, 201912
- Chief financial officerCharles A. Deignan Jun 1, 2016 to Jan 10, 202513
Board members and other officers (18)
- CHIEF MEDICAL OFFICERNgai Hang Victor Chong Mar 18, 2024 to Jan 10, 202514
- Chief Medical OfficerThomas Ciulla Jun 26, 2020 to Jan 20, 202315
- Chief Commercial OfficerBrion S. Raymond Feb 27, 2018 to Jun 4, 201916
- Executive Vice President, R&DGlenn Noronha Jun 1, 2016 to Dec 12, 201717
- Board memberAnthony S. Gibney Apr 16, 2024 to Jun 21, 202418
- Board memberBenjamin R. Yerxa Mar 4, 2022 to Jun 21, 202419
- Board memberNancy J. Hutson Apr 23, 2020 to Jun 21, 202420
- Board memberJeffrey L. Edwards Sep 28, 2018 to Jun 21, 202421
- Board memberGeorge M. Lasezkay Aug 10, 2017 to Jan 10, 202522
- Board memberChristy L. Shaffer Jun 1, 2016 to Jun 21, 202423
- Board memberClay Thorp Jun 1, 2016 to Feb 24, 202524
- Board memberDaniel H. White Jun 1, 2016 to Feb 7, 201912
- Board memberDerek Yoon Jun 1, 2016 to Jul 5, 201725
- Board memberEvgeny Zaytsev Jun 1, 2016 to Jun 21, 201826
- Board memberGerald D. Cagle Jun 1, 2016 to Jun 26, 201827
- Board memberRichard Croarkin Jun 1, 2016 to Jun 21, 202428
- Board memberWilliam D. Humphries Jun 1, 2016 to Jun 21, 202429
- Board memberBihua Chen Jun 13, 2016 to Jun 13, 201630
Timeline
Filings
187 filings to the SEC since October 2021: 4 annual reports, 13 quarterly reports, 48 major events, 69 insider forms, 11 large holders, 42 other. The latest 20:
- Jan 7, 202615-12G EDGAR
- Dec 29, 20258-K EDGAR
- Dec 16, 2025EFFECT EDGAR
- Dec 16, 2025EFFECT EDGAR
- Dec 15, 2025S-8 POS EDGAR
- Dec 15, 2025S-8 POS EDGAR
- Dec 15, 2025S-8 POS EDGAR
- Dec 15, 2025S-8 POS EDGAR
- Dec 15, 2025S-8 POS EDGAR
- Dec 15, 2025S-8 POS EDGAR
- Dec 15, 2025S-8 POS EDGAR
- Dec 15, 2025S-8 POS EDGAR
- Dec 15, 2025POS AM EDGAR
- Dec 15, 2025S-8 POS EDGAR
- Dec 15, 2025POS AM EDGAR
- Dec 15, 2025S-8 POS EDGAR
- Dec 8, 20258-K EDGAR
- Dec 8, 202525 EDGAR
- Nov 25, 20258-K EDGAR
- Nov 14, 202510-Q EDGAR
The 187 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 11 such filings since October 2021, the latest 10:
- Apr 1, 2025SCHEDULE 13G
- Mar 4, 2025SCHEDULE 13G/A
- Feb 21, 2025SCHEDULE 13D/A
- Nov 1, 2023SC 13G/A
- Feb 14, 2023SC 13G/A
- Feb 13, 2023SC 13G/A
- Jan 4, 2023SC 13D/A
- Jan 4, 2023SC 13G/A
- Feb 14, 2022SC 13G/A
- Feb 9, 2022SC 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARThomas Ciulla, Chief Medical Officer
- 16
- 17
- 18SEC EDGARAnthony S. Gibney, Board member
- 19SEC EDGARBenjamin R. Yerxa, Board member
- 20SEC EDGARNancy J. Hutson, Board member
- 21SEC EDGARJeffrey L. Edwards, Board member
- 22SEC EDGARGeorge M. Lasezkay, Board member
- 23SEC EDGARChristy L. Shaffer, Board member
- 24SEC EDGARClay Thorp, Board member
- 25SEC EDGARDerek Yoon, Board member
- 26SEC EDGAREvgeny Zaytsev, Board member
- 27SEC EDGARGerald D. Cagle, Board member
- 28SEC EDGARRichard Croarkin, Board member
- 29SEC EDGARWilliam D. Humphries, Board member
- 30SEC EDGARBihua Chen, Board member